PAN-90806 Ophthalmic Solution

DRUG3 trials

Sponsors

PanOptica, Inc., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Conditions

Age-Related Macular Degeneration (AMD)Diabetic RetinopathyNeovascular (Wet) Age-Related Macular DegenerationWet Age Related Macular Degeneration

Phase 1

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

CompletedNCT02022540

PanOptica, Inc.Age-Related Macular Degeneration (AMD)

Start: 2014-02-28End: 2016-05-31Updated: 2016-09-28

Study of Topical Ocular PAN-90806 in PDR

CompletedNCT02475109

PanOptica, Inc.Diabetic Retinopathy

Start: 2015-08-31End: 2016-07-31Updated: 2016-09-28

Evaluation of PAN-90806 Eye Drops in Healthy Subjects

Not yet recruitingNCT07764965

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Neovascular (Wet) Age-Related Macular Degeneration, Wet Age Related Macular Degeneration

Start: 2026-09-30End: 2026-12-30Target: 20Updated: 2026-08-14